News 2024-08-27
Connect with Porton at CPhI Europe 2024 @ Booth 5C17
CPhI Europe (October 8-10) in Milan, Italy, stands as a worldwide event in the pharmaceutical industry, bringing together key players, thought leaders, and businesses from across the globe. At this year's exhibition, Porton will showcase its end-to-end global CDMO service capabilities across both drug substance and drug product development and manufacturing and the differentiated advantages it offers to customers. From new drug development and process optimization to commercial manufacturing, Porton is dedicated to addressing customer needs and delivering efficient CDMO solutions at the highest quality and service levels. Our expertise spans from small molecules (DS-DP) to Tides, Biologics, and Conjugates.
With more than 62,000 professionals and 2,400 exhibitors hailing from over 166 countries, CPhI Europe is celebrated as one of the world's largest pharmaceutical trade show. This event serves as an unparalleled platform for powerful networking, fostering collaborations, and driving forward the pharmaceutical sector's growth and innovation.
For onsite meeting appointments, please contact: business@portonpharma.com.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
